The mission of the Cell Therapies Core Facility (CTF) is to produce the highest quality cellular products in support of novel, investigator-initiated clinical trials that employ cell-based therapies. The core works directly with cancer center investigators to translate promising bench level research into clinical scale products, including assisting with the FDA's INID approval process. The activities of the facility include collection of the necessary patient cells and/or tissues, manufacturing of products derived from those cells and tissues for clinical use;and support of post treatment monitoring by facilitation of immunologic monitoring and other specialized testing necessary to address the scientific endpoints of each study. The facility comprises: (i) an apheresis suite for mononuclear cell collection from blood by apheresis;(ii) a production area for standard processing, such as gradient isolation of lymphocytes or large scale cell washing, and specialized cell product manufacturing determined by study design;(iii) a cryostorage laboratory to provide large and small-scale, long and short-term liquid nitrogen cryostorage of cellular products for eventual clinical application or laboratory analysis;and (iv) the Cell Therapies Analytic Laboratory for quality and safety testing of products and specialized testing of patient derived samples associated with CTF supported clinical studies. In support of its mission, the CTF is accredited by the Foundation for Accreditation of Cellular Therapy, and is accredited jointly with the Moffitt clinical laboratory by AABB and the College of American Pathologists, and is thus a CLIA certified facility. The CTF has grown in size and activity to support the efforts of 13 investigators receiving support from 11 federally funded projects. The CTF has supported 18 clinical studies, including four that have been conducted at multiple centers. Since the last review cycle, multiple new products and their associated manufacturing methodologies have also been implemented, validated, and put into service to support clinical trials. The Core requests CCSG Support of $225,711, which is 27% of its operational budget. Over 85% of usage is by Moffitt members and peer-reviewed.

Public Health Relevance

The Cell Therapies Core is a valuable resource within Moffitt. Within this translational core is the wherewithal to translate laboratory scale concepts into clinical trial-ready products;to manufacture, release, and distribute those products according to applicable regulatory requirements;and to provide state-of-the-art immune monitoring support following administration of the test therapy. The core is at the heart of the process of bringing multiple products conceptualized by Moffitt members into clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-15
Application #
8495979
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$127,885
Indirect Cost
$51,989
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Perales-Puchalt, Alfredo; Perez-Sanz, Jairo; Payne, Kyle K et al. (2018) Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol 103:799-805
Davis, Stacy N; Govindaraju, Swapamthi; Jackson, Brittany et al. (2018) Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry. Nurs Res 67:212-221
Martínez, Úrsula; Brandon, Thomas H; Sutton, Steven K et al. (2018) Associations between the smoking-relatedness of a cancer type, cessation attitudes and beliefs, and future abstinence among recent quitters. Psychooncology 27:2104-2110
Kasting, Monica L; Giuliano, Anna R; Reich, Richard R et al. (2018) Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. Cancer Epidemiol Biomarkers Prev 27:503-513
Nelson, Ashley M; Jim, Heather S L; Small, Brent J et al. (2018) Sleep disruption among cancer patients following autologous hematopoietic cell transplantation. Bone Marrow Transplant 53:307-314
Singh, Kshipra; Coburn, Lori A; Asim, Mohammad et al. (2018) Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Cancer Res 78:4303-4315
Pidala, Joseph; Beato, Francisca; Kim, Jongphil et al. (2018) In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica 103:531-539
Denson, Aaron; Burke, Nancy; Wapinsky, Georgine et al. (2018) Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol 41:133-139
Betts, Brian C; Bastian, David; Iamsawat, Supinya et al. (2018) Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci U S A 115:1582-1587
Hoogland, Aasha I; Lechner, Suzanne C; Gonzalez, Brian D et al. (2018) Efficacy of a Spanish-Language Self-Administered Stress Management Training intervention for Latinas undergoing chemotherapy. Psychooncology 27:1305-1311

Showing the most recent 10 out of 1254 publications